NH SB400In Committeeas of 2026-02-26
Relative to duties and reporting requirements of the therapeutic cannabis medical oversight board.
Plain-English summary
What happened: A New Hampshire bill concerning the duties and reporting requirements of the therapeutic cannabis medical oversight board reached an impasse after the House refused to accede to a Senate request for a Committee of Conference.
Why it matters: A stalled update to the medical oversight board's reporting requirements leaves existing oversight structures unchanged, which affects how medical cannabis programs are monitored and how patients receive program protections.
Affects: patients and retailers
LATEST ACTION: House Refuses to Accede to Senate Request for CofC (Rep. Layon): Motion Adopted Voice Vote 05/21/2026 House Journal 14 P. 11
READ THE FULL BILL TEXT →Follow New Hampshire cannabis bills for free. One plain-English email a week with every bill that moved, including this one.
Get the free digestMore New Hampshire cannabis bills
SB624Restricting access to certain hemp-derived products and establishing the offenses of criminal adulteration and distribution of adulterated controlled substances.PassedHB1809Establishing a medical psilocybin advisory board to assess the advantages and disadvantages of the use of psilocybin for therapeutic purposes.In CommitteeSB461Relative to the definition of hemp.In CommitteeHB186Relative to the legalization and regulation of cannabis and making appropriations therefor.In CommitteeSB651Relative to the legalization and regulation of cannabis and making appropriations therefor.IntroducedSB650Relative to use of cannabis products for therapeutic purposes by alternative treatment centers.IntroducedHB1796Allowing the use of psilocybin in approved clinical settings to treat qualified medical conditions.IntroducedHB1446Providing that an individual's use of therapeutic cannabis shall not disqualify the individual from the purchase, ownership, or possession of a firearm.Introduced
ALL NEW HAMPSHIRECANNABIS LAWS & BILLS →Legislative data via LegiScan, licensed under CC BY 4.0. Summaries and categorization by CannaSignal. Regulatory information, not legal advice.